CLINICAL ROLE -
Empagliflozin Shows 10% Relative Risk Reduction in Time to First Hospitalization Due to Heart Failure
The finding did not reach statistical significance in the primary composite endpoint.
Read More
Study: Empagliflozin Reduces MACE Regardless of Baseline Albuminuria Levels
The results further confirm earlier findings from the EMPA-KIDNEY trial.
Pharmacy Technicians, Advanced Techs Can Do More in the Pharmacy
Studies have shown that the presence of advanced pharmacy technicians in a pharmacy has a positive predictive validity to increased monthly immunizations.
Changing Mindset Is Crucial for Clinicians to Effectively Implement New Weight Management Medications
In addition to improved efficacy, newer generations of anti-obesity medications have significantly improved safety concerns.
AI, Machine Learning Can Bring Significant Benefits to Pharmaceutical Development, Research
Identifying the best uses for these tools, whether in patient education, data collection, improving efficiencies, or other uses, could significantly improve the future of pharmacy.
“Food Is Medicine” Movement Takes Off
Integrate nutrition into the health care system with a proactive approach to chronic disease management
FDA Grants Accelerated Approval to Zanubrutinib for Relapsed, Refractory Follicular Lymphoma
The application was previously granted fast track designation and orphan drug designation.
Pharmacists Play Vital Role in Improving Vaccine Equity
Investing in community relationships and health literacy are key steps pharmacists can take to improve equity.
Adding Pembrolizumab to Chemotherapy Increases Pathological Complete Response, Improves Residual Cancer Burden in Early-Stage, High-Risk ER+/HER2– Breast Cancer
pCR rates improve regardless of whether patients received full chemotherapy doses.
FDA Experts Review Data, Regulatory Insights for New Metastatic Breast Cancer Therapies
Trastuzumab deruxtecan and elacestrant represent important new treatment options.
Abemaciclib, NSAI Extend Overall Survival for Patients With Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer
The combination resulted in numerically longer OS compared with an NSAI alone.
NATALEE Trial Data Demonstrate Reduction in Recurrence Risk Across Subgroups With Breast Cancer
Almost 80% of patients have now stopped treatment with ribociclib, but benefit persists and is greater than it was 6 months ago, according to the presenter.
The Future of Immunotherapy in Breast Cancer Involves Engineered T-Cell Therapies, Better Prediction of Adverse Effects
As the use of sequencing, proteomics, and immunopeptidomics increases, more targets will also be discovered, as well as more biomarkers that predict responses to treatments.
Tucatinib, Trastuzumab Combination Improves Progression-Free Survival in HER2+, Locally Advanced or Metastatic Breast Cancer
Improvements in PFS were also seen among patients with brain metastases.
Adding Pembrolizumab to Chemotherapy Increased Pathological Complete Response, Improved Residual Cancer Burden in Early-Stage, High-Risk ER+/HER2- Breast Cancer
pCR rates were improved with the addition of pembrolizumab regardless of whether patients received the full chemotherapy doses.
Abemaciclib, Nonsteroidal Aromatase Inhibitor Extends Overall Survival for Patients With HR+, HER2- Advanced Breast Cancer
MONARCH 3 final OS data show that the combination of abemaciclib and a NSAI in the first-line resulted in numerically longer OS compared to an NSAI alone.
Study: Patients With PD-L1-Positive, High-Risk, ER+/HER2- Breast Cancer Can Achieve Substantial Complete Response Rates With Addition of Nivolumab
Patients with an estrogen receptor measure greater than 8% and those with little to no TIL expression showed no benefit with the addition of nivolumab.
MONALEESA Pooled Analyses Show Quality of Life Is Maintained in Elderly Patients Receiving Ribociclib, Endocrine Therapy
The investigational combination also delayed the median time to first chemotherapy in all age groups.
New Capivasertib Approval Benefits Patients With Breast Cancer, PIK3CA/AKT1/PTEN Alterations
Biologic rationale, biomarker precision, and efficacy results in the biomarker-negative population all helped FDA officials decide the final indication.
Experts Say More Research Is Needed to Understand Obesity-Cancer Link
Evidence has shown that reversing pro-cancer effects requires significant weight loss as well as substantial metabolic reprogramming.
FDA Experts Review Data, Regulatory Insights for New Metastatic Breast Cancer Treatments
Trastuzumab deruxtecan and elacestrant both represent important new treatment options for subgroups of patients with breast cancer.
FDA Issues Fast Track Designation to ADP101 for Mono-, Multi-Food Allergies
The designation allows expedited development of ADP101 as a treatment for food allergy in children ages 4 to 17 with confirmed allergy to 1 or more of the 15 foods in the drug product.
FDA Approves Tirzepatide for Chronic Weight Management
Tirzepatide is already approved under the brand name Mounjaro (Lilly) to be used along with diet and exercise to improve blood sugar in adults with type 2 diabetes.
FDA Approves Secukinumab for Hidradenitis Suppurativa
The approval marks the first new biologic treatment option for this patient population in nearly a decade.
Study Links Long COVID With Short Sleep Duration
Risk of long COVID was 3 times higher in those who had pre-existing conditions and a short sleep duration, compared to those with no pre-existing conditions and adequate sleep.
FDA Approves Zilucoplan for Generalized Myasthenia Gravis in AChR Antibody-Positive Adults
The approval marks the first and only once-daily target therapy for generalized myasthenia gravis for self-administration in this patient population.
Scholarship Program Aims to Improve Diversity, Equity in Pharmacy Field
If health care professionals want to increase access and care in these underrepresented communities, an important first step is also increasing the representation of those groups in health care itself.
FDA Approves Secukinumab as First Intravenous Interleukin-17A Antagonist for Rheumatic Diseases
The intravenous formulation of secukinumab is administered in monthly 30-minute, weight-based dosing and requires no pre-medication or lab monitoring.
Study Finds IVIG, Therapeutic Plasma Exchange Have Comparable Efficacy for Neurological Disorders
Choice of therapy should be selected based on patient needs and conditions.
Survey Highlights Need for Improved Working Conditions, Communication in Pharmacies
Although respondents reported no impacts on patient safety, workload significantly increased during the COVID-19 pandemic and led to major burnout challenges.